147621-19-0

Basic information

• Product Name: 6-PYRIDIN-3-YL-1H-INDOLE
• Synonyms: 6-PYRIDIN-3-YL-1H-INDOLE
• CAS NO: 147621-19-0
• Molecular Formula: C13H10N2
• Molecular Weight: 194.23
• Mol File: 147621-19-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 420.1 °C at 760 mmHg
• Flash Point: 192.9 °C
• Appearance: /
• Density: 1.211 g/cm³
• Vapor Pressure: 7.07E-07mmHg at 25°C
• Refractive Index: 1.688
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-PYRIDIN-3-YL-1H-INDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-PYRIDIN-3-YL-1H-INDOLE(147621-19-0)
• EPA Substance Registry System: 6-PYRIDIN-3-YL-1H-INDOLE(147621-19-0)

Safety Data

• Hazardous Substances Data: 147621-19-0(Hazardous Substances Data)

Usage

General Description

6-Pyridin-3-yl-1H-indole is a chemical compound that belongs to the class of organic compounds known as indoles, which are aromatic heterocyclic compounds containing a benzene and a pyrrole ring fused together. The systematic name of this chemical is 2-(1H-indol-6-yl)pyridine. The key feature of 6-pyridin-3-yl-1h-indole is its indole core, a characteristic bicyclic system present in many natural products and biologically active molecules. The properties and reactivity of this compound can be influenced by the pyridine ring attached to the indole system. While the detailed information regarding its synthesis, properties, and potential applications are not extensively documented, its structure suggests that it may have potential applications in medicinal chemistry or materials science.

InChI:InChI=1/C13H10N2/c1-2-12(9-14-6-1)11-4-3-10-5-7-15-13(10)8-11/h1-9,15H

Upstream product

• 626-55-1 3-Bromopyridine 
• 147621-18-9 6-indolylboronic acid 
• 17422-33-2 6-chloroindole 
• 1692-25-7 3-pyridylboronic acid 
• 626-60-8 3-Chloropyridine 
• 52415-29-9 6-bromo-1H-indole 

Relevant articles and documents

Identification of an Indazole-Based Pharmacophore for the Inhibition of FGFR Kinases Using Fragment-Led de Novo Design

Structure-based drug design (SBDD) has become a powerful tool utilized by medicinal chemists to rationally guide the drug discovery process. Herein, we describe the use of SPROUT, a de novo-based program, to identify an indazole-based pharmacophore for the inhibition of fibroblast growth factor receptor (FGFR) kinases, which are validated targets for cancer therapy. Hit identification using SPROUT yielded 6-phenylindole as a small fragment predicted to bind to FGFR1. With the aid of docking models, several modifications to the indole were made to optimize the fragment to an indazole-containing pharmacophore, leading to a library of compounds containing 23 derivatives. Biological evaluation revealed that these indazole-containing fragments inhibited FGFR1-3 in the range of 0.8-90 μM with excellent ligand efficiencies of 0.30-0.48. Some compounds exhibited moderate selectivity toward individual FGFRs, indicating that further optimization using SBDD may lead to potent and selective inhibitors of the FGFR family.

Scope of the suzuki-Miyaura cross-coupling reactions of potassium heteroaryltrifluoroborates

A wide variety of bench-stable potassium heteroaryltrifluoroborates were prepared, and general reaction conditions were developed for their cross-coupling to aryl and heteroaryl halides. The cross-coupled products were obtained in good to excellent yields. This method represents an efficient and facile installation of heterocyclic building blocks onto preexisting organic substructures.

3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a Novel Series of Platelet Activating Factor Antagonists

(2RS,4R)-3-(2-(3-pyridinyl)thiazolidin-4-oyl)indoles represent a new class of potent, orally active antagonists of platelet activating factor (PAF). The compounds were prepared by acylation of the magnesium or zinc salts of substituted indoles with (2RS,4R)-2-(3-pyridinyl)-3-(tert-butoxycarbonyl)thiazolidin-4-oyl chloride. The 3-acylindole moiety functions as a hydrolytically stabilized and conformationally restricted anilide replacement, which imparts a considerable boost in potency to the series. Structure-activity relationships observed for substitution on the indole ring system are discussed. Members of the series compare favorably with other reported PAF antagonists.